Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 1Abbreviated Title: Personalized DC Vaccine CC Protocol Number: 17-C-0177 B IBC Number: RD-17-IV-07 NCT Number : NCT03300843 Version Date: March 26, 2018 PROTOCOL TITLE A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vac cine to Immunize Melanoma or Epithelial Cancer Patients Agains t Defined Mutated Neoantigens E xpressed by the Autologous Cancer NIH Principal Investigator: Steven A. Rosenberg, M.D., Ph.D. Chief of Surgery, Surgery Branch, NCIBuilding 10, CRC, Room 3-39409000 Rockville Pike, Bethesda, MD 20892Phone: 240-760-6218; Email: Stev en.Rosenberg@nih.gov Investigational Agents: Drug Name: Peptide load ed dendritic cell vaccine IND Number: 17564 Sponsor: Center for Cancer Research Manufacturer: Surgery Bra nch Cell Production Facility Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 2PRÉCIS Background: xTherapeutic vaccination against cancer has proven very challeng ing with little clinical benefit. xVaccines against non-viral tumors have mainly targeted differentiat ion antigens, cancer testis antigens, and overexpresse d antigens.